We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Inventiva publie ses informations financières du 3ème trimestre 2024¹ Trésorerie et équivalents de trésorerie à 13,9 millions d’euros au 30 septembre 2023.Chiffre d’affaires de 1,3 millions...
Inventiva reports 2024 Third Quarter Financial Information¹ Cash and cash equivalents at €13.9 million, as of September 30, 2024.Revenues of €1.3 million for the first nine months of 2024.On July...
Combined General Meeting of December 11, 2024 - Availability of the preparatory documents Daix (France), Long Island City (New York, United States), November 20, 2024 – Inventiva (Euronext Paris...
Statement of total voting rights and shares forming the company’s share capital as of November 4, 2024 Article R. 22-10-23 of the French Commercial Code Market : Euronext ParisISIN code /...
Information relative au nombre total de droits de vote et d’actions composant le capital social au 4 novembre 2024 Article R. 22-10-23 du Code de commerce Place de cotation : Euronext ParisCode...
Assemblée Générale Mixte du 11 décembre 2024 - Modalités de mise à disposition des documents préparatoires Daix (France), Long Island City (New York, Etats-Unis), le 20 novembre 2024 – Inventiva...
Inventiva présentera lors de la session « late-breaker » de l'AASLD The Liver Meeting®, les résultats de l'analyse finale de la Phase 2 évaluant la combinaison de lanifibranor avec...
Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting®...
Inventiva annonce la recommandation positive du cinquième DMC de l’étude clinique NATiV3 Phase 3 avec lanifibranor dans la MASH Le Data Monitoring Committee recommande sur la base d’une revue...
Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH The Data Monitoring Committee recommended to continue...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.015 | 0.62630480167 | 2.395 | 2.48 | 2.36 | 1885 | 2.41816996 | DE |
4 | 0.01 | 0.416666666667 | 2.4 | 2.64 | 2.36 | 690 | 2.43726584 | DE |
12 | 0.3400001 | 16.4251263973 | 2.0699999 | 3.21 | 1.452 | 2050 | 2.27283287 | DE |
26 | -0.775 | -24.3328100471 | 3.185 | 3.21 | 1.452 | 1436 | 2.30056502 | DE |
52 | -1.765 | -42.2754491018 | 4.175 | 4.335 | 1.452 | 1312 | 2.74037198 | DE |
156 | -0.855 | -26.1868300153 | 3.265 | 4.55 | 1.452 | 1275 | 2.90161632 | DE |
260 | -0.855 | -26.1868300153 | 3.265 | 4.55 | 1.452 | 1275 | 2.90161632 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions